Nanobiotix Shares Consolidate Nearly 27% Below Record High Despite Target Price Upgrade by Jefferies
The French biotech continues its consolidation phase after an extraordinary stock market journey. The stock declines during the session while the Paris market trends sharply upwards. This movement comes just days after a share placement operation.
Share Falls to €34.60, Dips Below the MM20 in a Rising SBF 120
Nanobiotix shares fell 2.15% to €34.60 in late afternoon trading, moving against the trend of an SBF 120 that is up 0.77% and a CAC 40 that has risen by 0.84%. The decline follows Tuesday's session, bringing the weekly performance to -10.08%. In terms of moving averages, the price has fallen below the MM20 at €36.24 (a gap of -4.53%), while still maintaining a significant cushion above the MM50 at €30.82 (+12.26%) and the MM200 at €20.55 (+68.37%). The RSI at 51 remains neutral, indicating a consolidation movement rather than a significant reversal. The performance remains impressive over longer horizons, with an increase of nearly 51% over three months and more than 900% over one year.
Market Digests an Extraordinary Journey
The session follows recent corporate events. On May 21, the biotech was suspended from trading on Euronext Paris for a global offering of shares, before Jefferies raised its target price on May 22 from €21.50 to €60, maintaining a buy recommendation. The clinical portfolio remains another pillar of the journey: data presented on May 18 from the Phase 2 CONVERGE study conducted with Johnson & Johnson reported an overall response rate of 85.7% for JNJ-1900 in non-small cell lung cancer. This sequence propelled the stock to a record high of €47.66 on May 18. Since then, the price has retracted by nearly 27% from this peak, in a logic of consolidation. The MM20 at €36.24 will be the next threshold to watch to gauge the continuation of the movement.
